Category Archives: Insulin Delivery

Structure, Senseonics, Tandem, and Biocon Q2 ’26 Earnings

A series of cardiometabolic-related news items has been observed from Structure Therapeutics, Senseonics, Tandem Diabetes Care, and Biocon. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Insulet, NewAmsterdam, Protagonist, and Biomea Q2 ’26 Earnings; Vivani Completes Initial Dosing for Sema Implant; CVS Expands GLP-1RA Support

A series of cardiometabolic-related news items has been observed from Insulet, NewAmsterdam Pharma, Protagonist Therapeutics, Biomea Fusion, Vivani Medical, and CVS Health. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Ionis Q2 ’26 Earnings; FDA Revised Draft Guidance for Generic AOMs; Beta Bionics Q2 ’26 Earnings

Three cardiometabolic-related news items have been observed: Ionis hosted its Q2 ’26 earnings call (press release; slides); FDA published revised draft guidance for 17 peptides (view press release); and Beta Bionics hosted its Q2 ’26 earnings call (view press release; slides). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

AZ Q2 ’26 Earnings; Ex-Dexcom Executive Joins Luna Diabetes; Ascletis Preclinical Tri-Agonist Data; Ionis Pediatric Olezarsen Study; Lexicon Ph3 Sota Study; Veru Ph2b Enobosarm Study

A series of cardiometabolic-related news items has been observed from AstraZeneca, Luna Diabetes, Ascletis Pharma, Ionis Pharmaceuticals, Lexicon Pharmaceuticals, and Veru. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Arrowhead Reports Positive Ph3 Plozasiran Data; Avaí Partners for Insulin-Producing Cells; Novo Posts AMAZE 9 Zenagamtide Study; MiniMed Flex System Covered by Medicare

A series of cardiometabolic-related news items has been observed from Arrowhead Pharmaceuticals, Avaí Bio, Novo Nordisk, and MiniMed. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Sues Lilly Over DTC Ads; Novartis Q2 ’26 Earnings; Aspen Generic Sema in Canada; Medtrum 300U Patch Pump to Launch in Germany; Hilo Launches Cuffless BP Monitor in US

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Novartis, Aspen Pharmacare, Medtrum, and Hilo. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Merck’s Oral PCSK9i Approved by FDA; BI Ph2 Triple Agonist Study; Abbott Q2 ’26 Earnings; Syntis Ph1 Obesity Data; Lilly Invests in Oura; Braveheart IPO

A series of cardiometabolic-related news items has been observed from Merck, Boehringer Ingelheim, Abbott, Syntis Bio, Oura/Lilly, and Braveheart. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Zverev Sports MiniMed at Wimbledon; CSPC/AZ Milestone Payment; Madrigal Rezdiffra Patents; Novo AMAZE 3 Zenagamtide Study

A series of cardiometabolic-related news items has been observed from MiniMed, CSPC Pharmaceutical, Madrigal Pharmaceuticals, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

AZ/CSPC CVRM Deal; Amgen Initiates New Ph1 T2DM Study; Ascletis Files US INDs; Regeneron Posts New Ph2 Olatorepatide Study; Trinity CGM+ Results; Wegovy MASH MHRA Approval; Adocia/Sanofi M1Pram Agreement Expiration; ViCentra Hybrid Closed Loop Germany Launch

A series of cardiometabolic-related news items has been observed from AstraZeneca/CSPC Pharmaceutical, Amgen, Ascletis Pharma, Regeneron Pharmaceuticals, Trinity Biotech, MHRA, Adocia, and ViCentra. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Medicare GLP-1 Bridge Program Initiates; Tandem’s t:slim Pump and Abbott’s FreeStyle Libre 3+ Launch in Select UK/EU Markets; Hengrui Posts Ph3 Oral Ribupatide Study in China; Terrestrial Bio Doses First Patient with Needle-Free Sema Patch Technology; Tufts Health Eliminates Coverage for Dexcom CGMs

A series of cardiometabolic-related news items has been observed from The Obesity Action Coalition, Hengrui, Terrestrial Bio, Tandem Diabetes Care, and Tufts Health Direct. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.

Already a member? Log in here